HIV drug combination for increasing barrier against resistance
AssigneeMerck Sharp & Dohme Corp.
InventorsDaria Jean Hazuda, Ming-Tain Lai
Life of this patent
Estimating the term…
Abstract
The instant invention relates to a method for reducing the risk for development of anti-viral treatment resistance due to an HIV mutation in a human subject infected with HIV, comprising administering EFdA in combination with one or more anti-viral agents.
Claims15
A method of reducing the risk for development of anti-viral treatment resistance due to an HIV mutation in a human subject infected with HIV, comprising administering an effective amount of EFdA in combination with one or more additional HIV antiviral drugs, wherein the additional antiviral drug is doravirine.
A method of reducing the risk for development of anti-viral treatment resistance due to an F227C HIV mutation in a human subject infected with HIV, comprising administering an effective amount of EFdA in combination with doravirine.
Dependencies are inferred from the claim text.